| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.23 | 5e-05 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.17 | 0.006 |
| mRNA | methylstat | CTRPv2 | pan-cancer | AAC | 0.11 | 0.006 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.006 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.007 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.008 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.095 | 0.008 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | -0.099 | 0.008 |